8-K: Relmada Regains Nasdaq Compliance, Averting Delisting

Relmada Therapeutics announced it has regained compliance with Nasdaq's $1.00 minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Summary

• Relmada Therapeutics, Inc. received written notice from the Nasdaq Stock Market LLC on September 15, 2025, confirming compliance with Nasdaq Listing Rule 5550(a)(2).
• The company's common stock maintained a closing bid price of $1.00 per share or greater for 10 consecutive trading days, from August 29, 2025, to September 12, 2025.
• Nasdaq has closed the matter, and Relmada is now in full compliance with all Nasdaq continued listing requirements.
• The company's stock will remain listed and traded on the Nasdaq Capital Market under the ticker RLMD.
• Relmada Therapeutics is a clinical-stage biotechnology company focused on developing therapies for oncology-related and central nervous system conditions, with lead candidates NDV-01 and sepranolone.

Sentiment

Score: 8

Explanation: The filing reports a positive resolution to a significant compliance issue, removing the immediate threat of delisting. This is a strong positive for the company's stability and market presence, though it does not directly address fundamental business performance or pipeline progress.

Positives

• Regained full compliance with Nasdaq's minimum bid price requirement, removing the risk of delisting.
• Ensures continued listing and trading of common stock on the Nasdaq Capital Market, maintaining market access and liquidity for investors.

Risks

• Potential for product candidates (NDV-01, sepranolone) to not progress as expected.
• Clinical trials may fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety.
• Top-line results may not accurately reflect the complete results of a trial.
• Planned or ongoing preclinical and clinical studies may fail to demonstrate expected results.
• Potential failure to secure FDA agreement on the regulatory path for NDV-01 and sepranolone.
• Future clinical results for NDV-01 or sepranolone may not be acceptable to the FDA.
• Failure to secure adequate drug supply for NDV-01 or sepranolone.

Future Outlook

Relmada Therapeutics continues to advance its lead candidates, NDV-01 and sepranolone, through mid-stage clinical development, aiming to address significant unmet needs in oncology-related and central nervous system conditions. The company's forward-looking statements highlight the potential for these candidates to progress and deliver positive clinical results, subject to various risks inherent in drug development and regulatory approval processes.

Industry Context

Regaining Nasdaq compliance is a significant event for small and mid-cap biotechnology companies, as maintaining a listing on a major exchange like Nasdaq is crucial for investor visibility, access to capital, and overall market credibility. Minimum bid price requirements are a common challenge for clinical-stage companies whose stock prices can be volatile due to development risks and lack of commercial revenue. This compliance update positions Relmada to continue its clinical development programs without the immediate threat of delisting, which is a common concern across the biotech sector for companies facing similar challenges.

Stakeholder Impact

• Shareholders: The continued listing on Nasdaq preserves liquidity and market access for their investment, removing a significant overhang.
• Employees: Provides stability and confidence in the company's operational continuity and future prospects.
• Customers/Partners: Maintains the company's credibility and ability to attract and retain partnerships for its drug development programs.

Next Steps

• Continue advancing lead candidates NDV-01 and sepranolone through mid-stage clinical development.
• Focus on securing FDA agreement on regulatory paths and achieving positive clinical results for product candidates.

Key Dates

Recommendation

The regaining of Nasdaq compliance removes a significant delisting risk, which is a positive development for Relmada Therapeutics. This action stabilizes the company's market position and investor confidence by ensuring continued access to a major exchange. However, this event does not fundamentally alter the company's core business prospects, which remain tied to the successful clinical development and commercialization of its drug candidates. While the removal of this overhang is beneficial, it does not provide new information warranting a 'buy' recommendation based on fundamental business performance, nor does it suggest a 'sell' given the positive resolution of a critical issue. Therefore, a 'hold' recommendation is appropriate as investors await further updates on the company's clinical pipeline and financial performance.

Keywords

Relmada Therapeutics, RLMD, Nasdaq compliance, minimum bid price, delisting, biotechnology, clinical-stage, oncology, central nervous system, NDV-01, sepranolone